Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...
Instil Bio stock falls after the company ends development of its lead cancer drug and exits a licensing deal, raising new ...
Intelligent Bio Solutions stock rises after announcing a manufacturing partnership targeting over 40% cost savings, major ...
The Phase 2a trial enrolled 35 IPF patients randomized in a 2:1 ratio to receive either GRI-0621 or placebo once daily for 12 weeks. A sub-study examined immune cells in bronchoalveolar lavage fluid ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...
Barchart on MSN
Here's What to Expect From Bio-Techne's Next Earnings Report
The leading life sciences reagents and instruments company is expected to announce its fiscal second-quarter earnings for ...
Instil Bio (NASDAQ:TIL) stock fell 15% Tuesday after the company announced that its wholly-owned subsidiary Axion Bio has decided to discontinue clinical developm ...
Key Insights Institutions' substantial holdings in Nuvation Bio implies that they have significant influence over ...
TipRanks on MSN
Why is Intelligent Bio Solutions stock (INBS) down today?
Intelligent Bio Solutions stock was down 14.06% in pre-market trading on Friday, following a 132.44% rally on the previous ...
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, advancing an “off‑the‑shelf ...
Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized ...
NEW YORK CITY, NEW YORK / ACCESS Newswire / January 10, 2026 / New to The Street, the nationally syndicated business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback